Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. - 2022
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma, María M; Sanchez, Lautaro; Ojeda, Diego Set al.
[en] Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. Longitudinal serum samples (N = 536) collected from 118 volunteers obtained between January and October 2021 were used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity for the Wuhan-related lineages of SARS-CoV-2 and VOC is maintained within 6 months of vaccination. In addition, an improved antibody cross-neutralizing ability for circulating variants of concern (Beta and Gamma) was observed over time postvaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least 6 months and show a reduction of VOC escape to neutralizing antibodies over time after vaccination. IMPORTANCE Vaccines have been produced in record time for SARS-CoV-2, offering the possibility of halting the global pandemic. However, inequalities in vaccine accessibility in different regions of the world create a need to increase international cooperation. Sputnik V is a recombinant adenovirus-based vaccine that has been widely used in Argentina and other developing countries, but limited information is available about its elicited immune responses. Here, we examined longitudinal antibody levels and viral neutralizing capacity elicited by Sputnik V vaccination. Using a cohort of 118 volunteers, we found that while anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern and local variants of interest is maintained within 4 months of vaccination. In addition, we observed an increased cross-neutralization activity over time for the Beta and Gamma variants. This study provides valuable information about the immune response generated by a vaccine platform used in many parts of the world.
Disciplines :
Immunology & infectious disease
Author, co-author :
Gonzalez Lopez Ledesma, María M; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Sanchez, Lautaro; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Ojeda, Diego S; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Oviedo Rouco, Santiago; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Rossi, Andrés H; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Varese, Augusto; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Mazzitelli, Ignacio; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Pascuale, Carla A; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Miglietta, Esteban A; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Rodríguez, Pamela E; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Pallarés, Horacio M; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Costa Navarro, Guadalupe S; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Caramelo, Julio J; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Rothlauf, Paul W; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
Liu, Zhuoming; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
Bloyet, Louis-Marie ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
Cornejo Pontelli, Marjorie; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
Rasetto, Natali Belen ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques ; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Wenker, Shirley D; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Ramis, Lila Y; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Bialer, Magalí G; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
de Leone, María Jose; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Hernando, C Esteban; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Bianchimano, Luciana; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Ríos, Antonella S; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Treffinger Cienfuegos, María Soledad; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Rodriguez García, Diana R; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Longueira, Yesica; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina ; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina
Laufer, Natalia; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina ; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina
Alvarez, Diego ; Instituto de Investigaciones Biotecnológicas, UNSAM-CONICET, Buenos Aires, Argentina
Ceballos, Ana; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Ochoa, Valeria; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Monzani, Cecilia; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Turk, Gariela; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina ; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina
Salvatori, Melina; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Carradori, Jorge; Laboratorio Lemos S.R.L., Buenos Aires, Argentina
Prost, Katherine; Hospital Interzonal General de Agudos Dr Pedro Fiorito, Buenos Aires, Argentina
Rima, Alejandra; Hospital Interzonal General de Agudos Evita, Buenos Aires, Argentina
Varela, Claudia; Hospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi, Buenos Aires, Argentina
Ercole, Regina; Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios, Buenos Aires, Argentina
Toro, Rosana I; Hospital Interzonal General de Agudos San Roque, Buenos Aires, Argentina
Gutierrez, Sebastian; Hospital Interzonal General de Agudos San Martín, Buenos Aires, Argentina
Zubieta, Martín; Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Buenos Aires, Argentina
Acuña, Dolores; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
Nabaes Jodar, Mercedes S; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
Torres, Carolina; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
Mojsiejczuk, Laura; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
Viegas, Mariana; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina
Velazquez, Pilar; Ministerio de Salud de Provincia de Buenos Aires, Buenos Aires, Argentina
Testa, Clarisa; Ministerio de Salud de Provincia de Buenos Aires, Buenos Aires, Argentina
Kreplak, Nicolas; Ministerio de Salud de Provincia de Buenos Aires, Buenos Aires, Argentina
Yanovsky, Marcelo; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Whelan, Sean ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA
Geffner, Jorge; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina
Pifano, Marina; Ministerio de Salud de Provincia de Buenos Aires, Buenos Aires, Argentina
Gamarnik, Andrea V ; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Agencia I+D+i NIAID - National Institute of Allergy and Infectious Diseases
Funding text :
This work was supported by NIH (NIAID) R01.AI095175 and PICT-2017-1717, PICT-2015-2555, and Fondo para la Convergencia Estructural del Mercosur (FOCEM) to A.V.G. and by the National Ministry of Science Technology and Innovation of Argentina.
World Health Organization. 2021. WHO coronavirus (COVID-19) dashboard with vaccination data. World Health Organization, Geneva, Switzerland.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27:1205–1207. https://doi.org/10.1038/s41591-021-01377-8.
Krammer F. 2021. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med 27:1147–1148. https://doi.org/10.1038/s41591-021-01432-4.
Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. 2021. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39:4423–4428. https://doi.org/10.1016/j.vaccine.2021.05.063.
Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, Hoffmann H-H, Barnes CO, Cipolla M, Ramos V, Oliveira TY, Cho A, Schmidt F, Da Silva J, Bednarski E, Aguado L, Yee J, Daga M, Turroja M, Millard KG, Jankovic M, Gazumyan A, Zhao Z, Rice CM, Bieniasz PD, Caskey M, Hatziioannou T, Nussenzweig MC. 2021. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595:426–431. https://doi.org/10 .1038/s41586-021-03696-9.
Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, De Angelis ML, Baratella M, Bazzigaluppi E, Venturi G, Sironi F, Canitano A, Marzinotto I, Tresoldi C, Ciceri F, Piemonti L, Negri D, Cara A, Lampasona V, Scarlatti G. 2021. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun 12:2670. https://doi.org/10.1038/s41467-021-22958-8.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, Hägglöf T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. 2021. Evolution of antibody immunity to SARS-CoV-2. Nature 591:639–644. https://doi.org/10.1038/ s41586-021-03207-w.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park E-S, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. 2021. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 54:1841–1852.e4. https://doi.org/10.1016/j.immuni.2021.06.015.
Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. 2021. Affinity maturation of SARSCoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity 54:1853–1816. https://doi.org/10.1016/j.immuni.2021.07.008.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396:887–897. https://doi.org/ 10.1016/S0140-6736(20)31866-3.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397:671–681. https://doi.org/10.1016/S0140-6736(21)00234-8.
Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I, Juliá AA, Rouco SO, Pallarés HM, Costa Navarro GS, Rasetto N, Garcia CI, Wenker SD, Ramis LY, Bialer MG, Jose de Leone M, Hernando CE, Sosa S, Bianchimano L, Rios A, Treffinger Cienfuegos MS, Caramelo JJ, Longueira Y, Laufer N, Alvarez D, Carradori J, Pedrozza D, Rima A, Echegoyen C, Ercole R, Gelpi P, Marchetti S, Zubieta M, Docena G, Kreplak N, Yanovsky M, Geffner J, Pifano M, Gamarnik AV. 2021. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS CoV-2 after a single dose. Cell Rep Med 2:100359. https://doi.org/10.1016/j.xcrm.2021.100359.
Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, Costa Navarro GS, Sanchez L, Perazzi B, Villordo SM, Alvarez DE, Echavarria M, Oguntuyo KY, Stevens CS, Lee B, Carradori J, Caramelo JJ, Yanovsky MJ, Gamarnik AV, Bio-Banco Working Group. 2021. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog 17:e1009161. https://doi.org/10.1371/journal.ppat.1009161.
Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. 2021. WHO international standard for anti-SARSCoV-2 immunoglobulin. Lancet 397:1347–1348. https://doi.org/10.1016/ S0140-6736(21)00527-4.
Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Droit L, Ilagan MXG, Tartell MA, Amarasinghe G, Henderson JP, Miersch S, Ustav M, Sidhu S, Virgin HW, Wang D, Ding S, Corti D, Theel ES, Fremont DH, Diamond MS, Whelan SPJ. 2002. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe 28:475–485. https://doi.org/10.1016/j.chom.2020.06.021.
Darvishi M, Rahimi F, Talebi Bezmin Abadi A. 2021. SARS-CoV-2 Lambda (C.37): an emerging variant of concern? Gene Rep 25:101378. https://doi.org/10.1016/j.genrep.2021.101378.
País P. 2021. Reporte no 15: vigilancia activa de variantes de SARS-CoV-2 en la CABA, provincias de Buenos Aires, Chaco, Córdoba, La Pampa, Neuquén y Santa Fe. Actualización 2020:1–11.
